{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"bioRxiv"}],"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T12:15:31Z","timestamp":1768479331663,"version":"3.49.0"},"posted":{"date-parts":[[2018,9,7]]},"group-title":"Cancer Biology","reference-count":75,"publisher":"openRxiv","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2018,9,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                <jats:p>\n                  Bladder cancer is the most frequent malignancy of the urinary system and is ranked the seventh most diagnosed cancer in men worldwide. About 70-75% of all newly diagnosed patients with bladder cancer will present disease confined to the mucosa or submucosa, the non-muscle invasive bladder cancer (NMIBC) subtype. Of those, approximately 70% will recur after transurethral resection (TUR). Due to this high rate of recurrence, patients are submitted to an intensive follow-up program that should be maintained throughout many years, or even throughout life, resulting in an expensive follow-up, with cystoscopy being the most cost-effective procedure for NMIBC screening. Currently, the gold standard procedure for detection and follow-up of NMIBC is based on the association of cystoscopy and urine cytology. As cystoscopy is a very invasive approach, over the years, many different non-invasive (both in serum and urine samples) assays have been developed in order to search genetic and protein alterations related to the development, progression and recurrence of bladder cancer.\n                  <jats:italic>TERT<\/jats:italic>\n                  promoter mutations and\n                  <jats:italic>FGFR3<\/jats:italic>\n                  hotspot mutations are the most frequent somatic alterations in bladder cancer and constitute the most reliable biomarkers for bladder cancer. Based on these findings, an ultra-sensitive assay called Uromonitor\n                  <jats:sup>\u00ae<\/jats:sup>\n                  was developed that corresponds to a urine-based assay capable of detecting trace amounts of the two most common alterations in NMIBC,\n                  <jats:italic>TERT<\/jats:italic>\n                  promoter and\n                  <jats:italic>FGFR3<\/jats:italic>\n                  mutation, in urine samples. The Uromonitor\n                  <jats:sup>\u00ae<\/jats:sup>\n                  test was performed in a cohort of 72 patients, firstly diagnosed with bladder cancer and under surveillance for NMIBC, to access its sensitivity and specificity in the detection of NMIBC recurrence. Uromonitor\n                  <jats:sup>\u00ae<\/jats:sup>\n                  was shown to be highly sensitive and specific in detecting recurrence of bladder cancer in patients under surveillance of non-muscle invasive bladder cancer.\n                <\/jats:p>","DOI":"10.1101\/410738","type":"posted-content","created":{"date-parts":[[2018,9,7]],"date-time":"2018-09-07T11:25:36Z","timestamp":1536319536000},"source":"Crossref","is-referenced-by-count":3,"title":["Uromonitor\n                  <sup>\u00ae<\/sup>\n                  as a novel sensitive and specific urine-based test for recurrence surveillance of patients with non-muscle invasive bladder cancer"],"prefix":"10.64898","author":[{"given":"Cristina","family":"Sampaio","sequence":"first","affiliation":[]},{"given":"Rui","family":"Batista","sequence":"additional","affiliation":[]},{"given":"Pedro","family":"Peralta","sequence":"additional","affiliation":[]},{"given":"Paulo","family":"Concei\u00e7\u00e3o","sequence":"additional","affiliation":[]},{"given":"Am\u00edlcar","family":"Sismeiro","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5504-6642","authenticated-orcid":false,"given":"Hugo","family":"Prazeres","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0871-1427","authenticated-orcid":false,"given":"Jo\u00e3o","family":"Vinagre","sequence":"additional","affiliation":[]},{"given":"Paula","family":"Soares","sequence":"additional","affiliation":[]}],"member":"54368","reference":[{"key":"2019072205435611000_410738v1.1","doi-asserted-by":"publisher","DOI":"10.1111\/iju.13376"},{"key":"2019072205435611000_410738v1.2","unstructured":"Ferlay J S.I. , Ervik M , Dikshit R , Eser S , Mathers C , Rebelo M , Parkin DM , Forman D , Bray, F. , GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer;, 2012."},{"key":"2019072205435611000_410738v1.3","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2017.22"},{"key":"2019072205435611000_410738v1.4","unstructured":"M. Babjuk, M.B. , E. Comp\u00e9rat , P. Gontero , A.H. Mostafid , J. Palou , B.W.G. van Rhijn , M. Roupr\u00eat , S.F. Shariat , R. Sylvester , R. Zigeuner , O. Capoun , D. Cohen , V. Hern\u00e1ndez , V. Soukup , EUA Guidelines on Non-muscle-invasive Bladder Cancer. Edn. presented at the EAU Annual Congress Copenhagen 2018. ISBN 978-94-92671-01-1., 2018."},{"issue":"3","key":"2019072205435611000_410738v1.5","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.eururo.2016.06.020","article-title":"Updated 2016 EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer","volume":"71","year":"2017","journal-title":"Eur Urol"},{"key":"2019072205435611000_410738v1.6","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)60491-8"},{"key":"2019072205435611000_410738v1.7","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.28147"},{"key":"2019072205435611000_410738v1.8","doi-asserted-by":"crossref","unstructured":"Antoine G. van der Heijden, J.A.W. , Recurrence, Progression, and Follow-up in Non-Muscle-Invasive Bladder Cancer. European Urology Supplements, 2009: p. 556\u2013562.","DOI":"10.1016\/j.eursup.2009.06.010"},{"issue":"10","key":"2019072205435611000_410738v1.9","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.urolonc.2016.05.028","article-title":"Follow-up in non-muscle-invasive bladder cancer-International Bladder Cancer Network recommendations","volume":"34","year":"2016","journal-title":"Urol Oncol"},{"issue":"11","key":"2019072205435611000_410738v1.10","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1007\/s40273-014-0194-2","article-title":"The health economics of bladder cancer: an updated review of the published literature","volume":"32","year":"2014","journal-title":"Pharmacoeconomics"},{"key":"2019072205435611000_410738v1.11","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2010.10026.x"},{"key":"2019072205435611000_410738v1.12","doi-asserted-by":"publisher","DOI":"10.1177\/1756287212454181"},{"issue":"2","key":"2019072205435611000_410738v1.13","doi-asserted-by":"crossref","first-page":"66 e25","DOI":"10.1016\/j.urolonc.2014.06.008","article-title":"Prospective analysis of sensitivity and specificity of urinary cytology and other urinary biomarkers for bladder cancer","volume":"33","year":"2015","journal-title":"Urol Oncol"},{"key":"2019072205435611000_410738v1.14","doi-asserted-by":"publisher","DOI":"10.3109\/10408363.2014.914888"},{"issue":"41","key":"2019072205435611000_410738v1.15","doi-asserted-by":"crossref","first-page":"67435","DOI":"10.18632\/oncotarget.11883","article-title":"Detection of multiple mutations in urinary exfoliated cells from male bladder cancer patients at diagnosis and during follow-up","volume":"7","year":"2016","journal-title":"Oncotarget"},{"key":"2019072205435611000_410738v1.16","doi-asserted-by":"crossref","unstructured":"Zwarthoff, E.C. , Detection of tumours of the urinary tract in voided urine. Scand J Urol Nephrol Suppl, 2008(218): p. 147\u201353.","DOI":"10.1080\/03008880802283953"},{"issue":"8 Pt 1","key":"2019072205435611000_410738v1.17","first-page":"1078","article-title":"Genetic analysis of DNA excreted in urine: a new approach for detecting specific genomic DNA sequences from cells dying in an organism","volume":"46","year":"2000","journal-title":"Clin Chem"},{"key":"2019072205435611000_410738v1.18","doi-asserted-by":"publisher","DOI":"10.1038\/ejhg.2015.281"},{"key":"2019072205435611000_410738v1.19","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(01)65851-8"},{"issue":"3","key":"2019072205435611000_410738v1.20","first-page":"400","article-title":"Performance characteristics of a new monoclonal antibody test for bladder cancer: ImmunoCyt trade mark","volume":"4","year":"1997","journal-title":"Can J Urol"},{"issue":"1","key":"2019072205435611000_410738v1.21","first-page":"41","article-title":"Numerical aberrations of chromosome 17 and the 9p21 locus are independent predictors of tumor recurrence in non-invasive transitional cell carcinoma of the urinary bladder","volume":"23","year":"2003","journal-title":"Int J Oncol"},{"key":"2019072205435611000_410738v1.22","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.3800262"},{"key":"2019072205435611000_410738v1.23","doi-asserted-by":"publisher","DOI":"10.1097\/PAP.0b013e3181832320"},{"key":"2019072205435611000_410738v1.24","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2006.10.044"},{"key":"2019072205435611000_410738v1.25","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.25651"},{"key":"2019072205435611000_410738v1.26","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0041162"},{"key":"2019072205435611000_410738v1.27","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0047469"},{"key":"2019072205435611000_410738v1.28","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-13-2498"},{"key":"2019072205435611000_410738v1.29","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.cca.2014.05.012","article-title":"Low- and high-grade bladder cancer appraisal via serum-based proteomics approach","volume":"436","year":"2014","journal-title":"Clin Chim Acta"},{"key":"2019072205435611000_410738v1.30","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2013.08.057"},{"key":"2019072205435611000_410738v1.31","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2013.08.052"},{"issue":"23","key":"2019072205435611000_410738v1.32","doi-asserted-by":"crossref","first-page":"12428","DOI":"10.18632\/oncotarget.2660","article-title":"TERT promoter mutations are associated with distant metastases in upper tract urothelial carcinomas and serve as urinary biomarkers detected by a sensitive castPCR","volume":"5","year":"2014","journal-title":"Oncotarget"},{"issue":"4","key":"2019072205435611000_410738v1.33","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1586\/14737159.2015.1019477","article-title":"Epigenetic biomarkers in the blood of patients with urological malignancies","volume":"15","year":"2015","journal-title":"Expert Rev Mol Diagn"},{"key":"2019072205435611000_410738v1.34","doi-asserted-by":"crossref","unstructured":"Springer, S.U. , et al, Non-invasive detection of urothelial cancer through the analysis of driver gene mutations and aneuploidy. Elife, 2018. 7.","DOI":"10.1101\/203968"},{"key":"2019072205435611000_410738v1.35","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(01)61918-9"},{"issue":"10","key":"2019072205435611000_410738v1.36","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1002\/cncy.21327","article-title":"Evaluation of urovysion and cytology for bladder cancer detection: a study of 1835 paired urine samples with clinical and histologic correlation","volume":"121","year":"2013","journal-title":"Cancer Cytopathol"},{"issue":"6","key":"2019072205435611000_410738v1.37","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1245\/s10434-016-5763-5","article-title":"Anticipatory Positive Urine Tests for Bladder Cancer","volume":"24","year":"2017","journal-title":"Ann Surg Oncol"},{"key":"2019072205435611000_410738v1.38","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2007.06.002"},{"issue":"4","key":"2019072205435611000_410738v1.39","doi-asserted-by":"crossref","first-page":"265","DOI":"10.5301\/urologia.5000041","article-title":"Urinary markers in the everyday diagnosis of bladder cancer","volume":"80","year":"2013","journal-title":"Urologia"},{"key":"2019072205435611000_410738v1.40","doi-asserted-by":"publisher","DOI":"10.1100\/tsw.2011.104"},{"key":"2019072205435611000_410738v1.41","doi-asserted-by":"publisher","DOI":"10.7326\/M15-0997"},{"issue":"7","key":"2019072205435611000_410738v1.42","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1002\/ijc.29526","article-title":"Mutations in TERT promoter and FGFR3 and telomere length in bladder cancer","volume":"137","year":"2015","journal-title":"Int J Cancer"},{"key":"2019072205435611000_410738v1.43","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1310522110"},{"key":"2019072205435611000_410738v1.44","doi-asserted-by":"publisher","DOI":"10.1007\/s00428-014-1608-4"},{"issue":"4","key":"2019072205435611000_410738v1.45","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/bjc.2017.210","article-title":"Non-invasive prediction of recurrence in bladder cancer by detecting somatic TERT promoter mutations in urine","volume":"117","year":"2017","journal-title":"Br J Cancer"},{"key":"2019072205435611000_410738v1.46","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(00)01055-4"},{"key":"2019072205435611000_410738v1.47","doi-asserted-by":"publisher","DOI":"10.1038\/nrurol.2011.193"},{"key":"2019072205435611000_410738v1.48","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2016.02.028"},{"key":"2019072205435611000_410738v1.49","doi-asserted-by":"publisher","DOI":"10.1038\/12615"},{"key":"2019072205435611000_410738v1.50","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1204110"},{"key":"2019072205435611000_410738v1.51","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9440(10)64665-2"},{"key":"2019072205435611000_410738v1.52","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.05.073"},{"issue":"22","key":"2019072205435611000_410738v1.53","first-page":"3664","article-title":"Prospective study of FGFR3 mutations as a prognostic factor in nonmuscle invasive urothelial bladder carcinomas","volume":"24","year":"2003","journal-title":"J Clin Oncol"},{"key":"2019072205435611000_410738v1.54","doi-asserted-by":"publisher","DOI":"10.1002\/path.2207"},{"issue":"4","key":"2019072205435611000_410738v1.55","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.urolonc.2010.07.014","article-title":"Oncogenic role of fibroblast growth factor receptor 3 in tumorigenesis of urinary bladder cancer","volume":"31","year":"2013","journal-title":"Urol Oncol"},{"key":"2019072205435611000_410738v1.56","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-007-0213-4"},{"key":"2019072205435611000_410738v1.57","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2011.12.001"},{"key":"2019072205435611000_410738v1.58","doi-asserted-by":"publisher","DOI":"10.1126\/science.1230062"},{"key":"2019072205435611000_410738v1.59","doi-asserted-by":"publisher","DOI":"10.1126\/science.1229259"},{"key":"2019072205435611000_410738v1.60","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1303607110"},{"key":"2019072205435611000_410738v1.61","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-13-0210"},{"key":"2019072205435611000_410738v1.62","doi-asserted-by":"publisher","DOI":"10.4161\/cc.24662"},{"key":"2019072205435611000_410738v1.63","doi-asserted-by":"crossref","unstructured":"Nault, J.C. , et al, High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions. Nat Commun, 2014: p. 2218.","DOI":"10.1038\/ncomms3218"},{"key":"2019072205435611000_410738v1.64","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms3185"},{"key":"2019072205435611000_410738v1.65","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2013.10.038"},{"key":"2019072205435611000_410738v1.66","doi-asserted-by":"publisher","DOI":"10.1016\/0959-8049(95)00287-S"},{"key":"2019072205435611000_410738v1.67","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2012.11.005"},{"key":"2019072205435611000_410738v1.68","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1471-2490-14-5","article-title":"Long term follow-up in patients with initially diagnosed low grade Ta non-muscle invasive bladder tumors: tumor recurrence and worsening progression","volume":"14","year":"2014","journal-title":"BMC Urol"},{"key":"2019072205435611000_410738v1.69","doi-asserted-by":"publisher","DOI":"10.1002\/path.2507"},{"key":"2019072205435611000_410738v1.70","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2007.12.026"},{"issue":"1","key":"2019072205435611000_410738v1.71","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.juro.2011.09.008","article-title":"The FGFR3 mutation is related to favorable pT1 bladder cancer","volume":"187","year":"2012","journal-title":"J Urol"},{"key":"2019072205435611000_410738v1.72","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-3013"},{"key":"2019072205435611000_410738v1.73","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.2009.01334.x"},{"issue":"1","key":"2019072205435611000_410738v1.74","first-page":"48","article-title":"Gene-based urinary biomarkers for bladder cancer: an unfulfilled promise?","volume":"32","year":"2014","journal-title":"Urol Oncol"},{"key":"2019072205435611000_410738v1.75","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/95.8.588"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1101\/410738","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T22:53:46Z","timestamp":1768431226000},"score":1,"resource":{"primary":{"URL":"http:\/\/biorxiv.org\/lookup\/doi\/10.1101\/410738"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,7]]},"references-count":75,"URL":"https:\/\/doi.org\/10.1101\/410738","relation":{},"subject":[],"published":{"date-parts":[[2018,9,7]]},"subtype":"preprint"}}